Reaua Bee Venom Tag Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily identifiable. Plantar warts are specifically located on the soles of the feet, presenting as tender to touch and exhibiting an interrupted footprint pattern.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is important to allow the application to dry fully.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected or reddened, as this may exacerbate the condition. The product should also not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes due to the potential for adverse reactions.

Additionally, individuals with diabetes or poor blood circulation should avoid using this product, as these conditions may increase the risk of complications.

Contact with the eyes must be avoided. In the event of accidental exposure, the eyes should be flushed with water for 15 minutes.

Warnings and Precautions

For external use only. In the event of accidental ingestion, immediate medical assistance should be sought by contacting the Poison Control Center at 1-800-222-1222.

This product is contraindicated for use on irritated skin or any area that exhibits signs of infection or redness. It should not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes. Caution is advised for individuals with diabetes or those who have compromised blood circulation.

If discomfort persists following application, the user should discontinue use and consult a healthcare professional for further evaluation and guidance.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists. This recommendation is crucial to ensure safety and address any potential underlying issues that may arise during treatment.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Reaua Bee Venom Tag Wart Remover (salicylic acid 16% bee venom 1% bee venom tag wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought by contacting the Poison Control Center at 1-800-222-1222.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The available prescribing information does not provide specific data regarding the use of this product during pregnancy. There are no contraindications noted for use in pregnant patients, nor are there any associated risks to the fetus identified in the available literature. Additionally, no dosage modifications or special precautions for use during pregnancy are mentioned. Healthcare professionals should consider the lack of data when prescribing this product to women of childbearing potential and weigh the potential benefits against any unknown risks.

Lactation

There is no specific information available regarding the use of this product in lactating mothers. Additionally, there is no data concerning the potential for excretion of the product in breast milk or its effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers on the use of this product.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or a medical toxicologist may also be beneficial in managing the case effectively.

It is crucial to document all findings and interventions in the patient's medical record to ensure continuity of care and facilitate further management.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important for patients to understand the seriousness of this action and to act promptly.

Patients should be instructed to discontinue use and consult a doctor if they experience persistent discomfort after using the product. This guidance is crucial for ensuring patient safety and addressing any adverse reactions effectively.

Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes. In the event that the product does come into contact with the eyes, patients should be advised to flush the affected area with water for at least 15 minutes.

Patients must be reminded that the product is non-edible and should be stored securely. They should be instructed to cap the product tightly and keep it at room temperature, away from heat sources, to maintain its efficacy and safety.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that the storage environment does not exceed excessive heat, defined as 37°C (99°F). Proper handling should be observed to maintain the integrity of the product throughout its shelf life.

Additional Clinical Information

The medication is administered topically, with the recommended frequency being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Reaua Bee Venom Tag Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)